DP
Diadema Partners Portfolio holdings
AUM
$161M
This Quarter Return
+3.6%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$88.7M
AUM Growth
–
Cap. Flow
+$88.7M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
58.9%
Holding
86
New
54
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 2 |
AbbVie
ABBV
|
$8.89M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$6.68M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$5.6M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$4.2M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $9.05M | 3.88% | +160,000 | New | +$9.05M |
|
|
2
AbbVie
ABBV
$372B
| $8.89M | 3.81% | +50,000 | New | +$8.89M |
|
|
3
Teva Pharmaceuticals
TEVA
$21.1B
| $6.68M | 2.86% | +300,000 | New | +$6.68M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $5.6M | 2.4% | +64,193 | New | +$5.6M |
|
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $4.2M | 1.8% | +75,000 | New | +$4.2M |
|
6
AstraZeneca
AZN
$248B
| $3.93M | 1.69% | +30,000 | New | +$3.93M |
|
7
Insmed
INSM
$28.8B
| $3.89M | 1.67% | +56,337 | New | +$3.89M |
|
8
Ascendis Pharma
ASND
$11.8B
| $3.48M | 1.49% | +25,276 | New | +$3.48M |
|
9
Tarsus Pharmaceuticals
TARS
$2.47B
| $3.32M | 1.43% | +60,000 | New | +$3.32M |
|
10
Soleno Therapeutics
SLNO
$3.6B
| $3.24M | 1.39% | +71,988 | New | +$3.24M |
|
11
Arcus Biosciences
RCUS
$1.13B
| $2.47M | 1.06% | +165,965 | New | +$2.47M |
|
12
Scholar Rock
SRRK
$3.14B
| $2.3M | 0.99% | +53,160 | New | +$2.3M |
|
13
Apogee Therapeutics
APGE
$2.17B
| $2.29M | 0.98% | +50,620 | New | +$2.29M |
|
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.21M | 0.95% | +131,862 | New | +$2.21M |
|
15
Relay Therapeutics
RLAY
$619M
| $2.08M | 0.89% | +505,778 | New | +$2.08M |
|
16
Jazz Pharmaceuticals
JAZZ
$7.75B
| $1.81M | 0.78% | +14,719 | New | +$1.81M |
|
17
Oric Pharmaceuticals
ORIC
$994M
| $1.73M | 0.74% | +214,291 | New | +$1.73M |
|
18
TG Therapeutics
TGTX
$4.65B
| $1.44M | 0.62% | +47,805 | New | +$1.44M |
|
19
Replimune Group
REPL
$422M
| $1.38M | 0.59% | +114,000 | New | +$1.38M |
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.32M | 0.57% | +25,900 | New | +$1.32M |
|
21
VistaGen Therapeutics
VTGN
$102M
| $1.31M | 0.56% | +442,520 | New | +$1.31M |
|
22
Denali Therapeutics
DNLI
$2.23B
| $1.22M | 0.52% | +60,000 | New | +$1.22M |
|
23
Nuvalent
NUVL
$5.52B
| $1.15M | 0.49% | +14,701 | New | +$1.15M |
|
24
Evolus
EOLS
$494M
| $1.08M | 0.46% | +97,423 | New | +$1.08M |
|
25
Keros Therapeutics
KROS
$618M
| $1.01M | 0.43% | +63,547 | New | +$1.01M |
|